Breast Cancer News
In this section, access cutting-edge news about breast cancer in young women including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A study looking at differences between tamoxifen-only treatment and tamoxifen plus ovarian function suppression, or OFS, in certain premenopausal women with early-stage breast cancer, found the OFS group experienced more difficulty with menopausal symptoms and other side effects.
When measured before chemotherapy, along with age, the level of a hormone released in young women’s ovaries may predict whether the ovaries will work again after chemotherapy.
The largest study of long-term breast cancer treatment using methods to stop estrogen production in premenopausal women with hormone receptor-positive disease has found what one of its authors calls “practice-changing” results for certain women.
Researchers found that immediate breast reconstruction, surgery to rebuild the breast done at the same time as mastectomy, is most likely to be used by young women in big cities who have private insurance and few chronic medical problems. Overall though, more women do NOT have their breasts rebuilt at that time.
Highlights from the annual San Antonio Breast Cancer Symposium held December 9-13, 2014 including presentation of results from a new survey conducted by Living Beyond Breast Cancer on the psychosocial needs of women with triple-negative breast cancer.
A study of young women diagnosed with stage I-III breast cancer using traditional staging methods found that later PET/CT scans changed 21 percent of those diagnoses to stage III or IV.
An article published in JAMA Surgery suggests that even while some state laws are mandating changes in the way doctors discuss the safety of breast implants and the pros and cons of having immediate or delayed reconstruction, gaps in education still remain.
A recent study of California women with early-stage breast cancer showed that bilateral mastectomy has the same impact on survival as breast-conserving surgery, or lumpectomy, followed by radiation therapy.
After evaluating long-term results from recent studies, the American Society of Clinical Oncology, ASCO, issued a guideline update for tamoxifen therapy for hormone receptor-positive breast cancer.
The update advises doctors to offer up to 10 years of tamoxifen treatment, instead of the previous standard 5-year duration
LBBC highlights results of a phase III clinical trial studying a medicine used to protect premenopausal women’s ovaries during chemotherapy. Findings were announced during the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.